AO44: an improved hyperglycemic agent.
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D001794:Blood Pressure / Q000187:drug effects; D003981:Diazoxide / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004837:Epinephrine / Q000097:blood; D005260:Female; D006943:Hyperglycemia / Q000139:chemically induced; D006946:Hyperinsulinism / Q000188:drug therapy; D007003:Hypoglycemia / Q000188:drug therapy; D066298:In Vitro Techniques; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007329:Insulin Antagonists; D000078790:Insulin Secretion; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D014044:Tolbutamide / Q000494:pharmacology
D001786:Blood Glucose; D007328:Insulin; D007329:Insulin Antagonists; D014044:Tolbutamide; D003981:Diazoxide; D009638:Norepinephrine; D004837:Epinephrine